You are here

Clinical Trials: Cord Blood

Condition:   Cell Transplantation
Interventions:   Drug: Pneumostem;   Drug: Normal saline
Sponsor:   Samsung Medical Center
Recruiting - verified April 2017
Condition:   Deficiency of Anterior Cruciate Ligament
Interventions:   Biological: Cartistem(TM);   Biological: hyaluronic acid;   Procedure: ACL reconstruction only
Sponsor:   Samsung Medical Center
Completed
Conditions:   Leukemia;   Lymphoma;   Myeloma;   Myeloproliferative Diseases
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Clofarabine;   Drug: Rabbit ATG;   Radiation: Total Body Irradiation (TBI);   Procedure: Cord Blood Infusions;   Drug: Rituximab;   Drug: Cyclophosphamide;   Procedure: Natural Killer Cell Infusion;   Drug: Melphalan;   Drug: Mesna
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Cancer Prevention Research Institute of Texas
Recruiting
Conditions:   Hematological Malignancies;   Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Myelogenous Leukemia (CML);   Myelodysplastic Syndrome (MDS)
Interventions:   Drug: NiCord®;   Other: Cord Blood Unit
Sponsor:   Gamida Cell ltd
Recruiting - verified December 2016
Condition:   Inherited Metabolic Disorders (IMD)
Intervention:   Drug: Umbilical cord blood transplantation with HSC835
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified March 2017
Condition:   Hematologic Malignancy
Intervention:   Biological: Transplantation of cord blood expanded with UM171
Sponsors:   Maisonneuve-Rosemont Hospital;   Canadian Cancer Society Research Institute (CCSRI);   Canadian Institutes of Health Research (CIHR);   Hopital de l'Enfant-Jesus;   Vancouver General Hospital;   St. Justine's Hospital
Recruiting - verified March 2017
Condition:   Lymphoma
Interventions:   Procedure: Allogeneic stem cell transplantation;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: Methotrexate
Sponsors:   Massachusetts General Hospital;   Adienne SA;   Dana-Farber Cancer Institute
Withdrawn - verified March 2017
Condition:   Hematologic Neoplasms
Intervention:   Procedure: Allogeneic (Allo) hematopoietic stem cell transplantation
Sponsor:   Institut Paoli-Calmettes
Recruiting - verified March 2017
Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions:   Biological: haplo-identical cells (donor);   Biological: umbilical cord blood unit (CBU)
Sponsor:   Weill Medical College of Cornell University
Recruiting
Condition:   Hematologic Neoplasms
Intervention:   Procedure: T-Cell replete haplo-transplant
Sponsors:   University of Calgary;   The Canadian Blood and Marrow Transplant Group
Completed

Pages